Repligen (RGEN) Stock Valuation After RBC Coverage Resumes And Q1 2026 Beat

RBC coverage and Q1 earnings put Repligen (RGEN) back in focus

RBC Capital’s decision to resume coverage of Repligen (RGEN) with a favorable view, following Q1 2026 results that topped revenue and adjusted EPS forecasts, has put the stock back on many investors’ watchlists.

See our latest analysis for Repligen.

Repligen’s share price has climbed 26.95% over the past 30 days and 13.45% over 90 days, yet remains down 20.54% year to date, while the 1 year total shareholder return is 2.41%, indicating that momentum has recently picked up after a tougher stretch.

If strong Q1 numbers and fresh analyst coverage have you looking beyond a single stock, this may be a good moment to widen your watchlist with 40 healthcare AI stocks

With the stock still down year to date but trading at a discount to both analyst price targets and some intrinsic value estimates, investors now face a familiar question: Is this genuine upside potential, or is the market already pricing in future growth?

Most Popular Narrative: 29% Undervalued

Repligen’s fair value in the most followed narrative sits at $183.88 versus a last close of $130.59, putting a sizable valuation gap in focus.

Repligen is investing in expanding dual manufacturing (U.S. and Europe) and increasing APAC presence to address growing customer demand for greater supply chain security and regionalization, which should drive resilient sales globally and reduce revenue concentration risk.

Read the complete narrative.

Want to understand why this narrative supports a higher price tag? It leans on faster revenue growth, fatter margins, and a premium future earnings multiple. Curious how those pieces fit together into that fair value target? The full narrative lays out the math behind that story.

Result: Fair Value of $183.88 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, there are still clear pressure points, including softer funding for small biotech customers and exposure to gene therapy and AAV, which could unsettle revenue and margins.

Wall Street’s queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab’s valuation page.

Another View: Rich P/E Ratios Tell a Different Story

The popular narrative leans on a discounted cash flow style fair value that frames Repligen as 29% undervalued, yet the current P/E of about 143x tells a very different story when set against the global Life Sciences average of 34.6x, a peer average of 47.6x and a fair ratio of 29.3x.

In plain terms, the stock trades at roughly 4x the global industry multiple and nearly 5x its own fair ratio. This points to meaningful valuation risk if growth or sentiment cools. The question for you is whether that multiple gap reflects real long term potential or expectations that are already stretched.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on value and growth in play, this is a good time to look at the data yourself and decide where you stand. To weigh up both sides of the story, check out the 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

Do not stop at one stock when there are plenty of other opportunities you can quickly filter by quality, risk, and income using the Simply Wall Street Screener.

Target potential mispricings by reviewing companies flagged in the 44 high quality undervalued stocks to see which ones might deserve a closer look.
Prioritize resilience by scanning for companies in the 71 resilient stocks with low risk scores that score well on stability and balance sheet strength.
Hunt for early standouts by checking the screener containing 20 high quality undiscovered gems before these ideas sit on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.